Scopolamine and ketamine: evidence of convergence?
LM Monteggia, ET Kavalali - Biological psychiatry, 2013 - biologicalpsychiatryjournal.com
Recent findings have demonstrated that the noncompetitive N-methyl-D-aspartate (NMDA)
receptor antagonist ketamine and the muscarinic acetylcholine receptor antagonist
scopolamine have rapid antidepressant effects in depressed individuals (1-3). Patients
resistant to other treatments reported alleviation of core major depression symptoms
following infusion of low-dose ketamine or scopolamine, with effects lingering for longer than
2 weeks in some patients. The rapid efficacy of these compounds is in striking contrast to …
receptor antagonist ketamine and the muscarinic acetylcholine receptor antagonist
scopolamine have rapid antidepressant effects in depressed individuals (1-3). Patients
resistant to other treatments reported alleviation of core major depression symptoms
following infusion of low-dose ketamine or scopolamine, with effects lingering for longer than
2 weeks in some patients. The rapid efficacy of these compounds is in striking contrast to …